ResApp Health (ASX:RAP), a digital health company developing smartphone applications for the diagnosis and management of respiratory disease, says its ResAppDx-EU smartphone-based acute respiratory diagnostic test has been under evaluation at a federal government-funded COVID-19 respiratory clinic in Brisbane for the past month.
ResApp says it has now provided the clinic with a license for the clinical use of ResAppDx-EU at no cost through to September this year.
Health Hub Doctors Morayfield was the first respiratory clinic established with federal government funding to take the pressure off local hospitals by treating mild-moderate respiratory illnesses and assessing patients requiring COVID-19 testing. The clinic sees up to 300 patients per day and has 65 general practitioners on staff.
Te company said ResAppDx-EU is being used by doctors at the clinic to triage patients who present with respiratory symptoms, helping identify illnesses such as lower respiratory tract infections, pneumonia, asthma exacerbations and COPD exacerbations.
“Mild-moderate respiratory illnesses are the most common conditions that we see, with many patients presenting with respiratory symptoms that may or may not be COVID-19 related,” said Dr Evan Jones, director of Health Hub Doctors Morayfield and Associate Professor of the University of the Sunshine Coast.
“Our doctors have found ResAppDx-EU invaluable in helping them make differential diagnoses of respiratory disease. Being a non-contact diagnostic aid, ResAppDx-EU is especially useful when assessing patients in the difficult conditions associated with managing possible COVID-19 cases.”
Tony Keating, CEO and managing director of ResApp added, “Our goal is to help doctors continue to make high-quality diagnoses even in the challenging conditions they currently face, where patient examinations require enhanced levels of personal protective equipment or are restricted to telehealth. We are pleased to provide Health Hub Doctors Morayfield with a no-cost license to assist during the COVID-19 pandemic and generate further real-world evidence of how ResAppDx-EU enhances the diagnosis and treatment of patients presenting with respiratory symptoms.”